African Americans with interstitial lung disease (ILD) caused by scleroderma (SSc-ILD) had largely similar outcomes compared to non‐African Americans in two clinical trials testing immunosuppressive therapies, according to an analysis.  Because all trial participants received the same treatment and follow‐up, the worse outcomes for African Americans with SSc-ILD found in prior studies may reflect other factors such as access to care, the scientists said.  The analysis, “Racial Disparities in Systemic Sclerosis: Short‐ and Long‐Term Outcomes Among…

You must be logged in to read/download the full post.